Table 7.

Therapeutic effects of OPC-20011 and VCM in an experimental murine model of respiratory tract infection caused by MRSA 5143a

CompoundDose (mg/kg)Log viable bacilli in lungsb (± SD)
Control07.81 ± 0.75
OPC-200112.55.92 ± 1.23
53.58 ± 0.47**
102.21 ± 0.76**
VCM57.14 ± 1.32
105.35 ± 1.47*
204.48 ± 0.51**
  • a Challenge dose was 5.5 × 106 CFU/mouse.

  • b Viable bacilli in lungs were counted at 24 h after final treatment. The difference between the control and each treated group was determined by using a two-tailed Dunnett’s test (*, P < 0.05; **, P < 0.01).